drugset / Trial / NCT03826992
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the safety and tolerability of combining venetoclax with Vyxeos (CPX-351) in pediatric and young adult patients with acute leukemia that has come back or not responded to treatment.
Timeline
- Start
- 2018-12-27
- Primary completion
- 2027-01
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPX-351 | Other / unclassified | 44 mg/m2 | Intravenous |
| Subject | CPX-351 | Other / unclassified | 100 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | — | Oral |